Related references
Note: Only part of the references are listed.Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study
Carme Loras et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients
Sophia Li et al.
CLINICAL RHEUMATOLOGY (2009)
Risk of Cervical Abnormalities in Women With Inflammatory Bowel Disease: A Population-Based Nested Case-Control Study
Harminder Singh et al.
GASTROENTEROLOGY (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti-TNF-α Agents
Anja Strangfeld et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Development of primary varicella infection during infliximab treatment for psoriasis
Nicola Balato et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Anti-TNF- therapy for rheumatoid arthritis among patients with chronic hepatitis B infection
Helena Robinson et al.
RHEUMATOLOGY (2009)
Higher Incidence of Abnormal Pap Smears in Women With Inflammatory Bowel Disease
Sunanda Kane et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Hepatosplenic T cell lymphoma in inflammatory bowel disease
Matthew Shale et al.
GUT (2008)
JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
J. Verbeeck et al.
GUT (2008)
Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B
Maurizio Benucci et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2008)
Herpes zoster in patients taking TNFα antagonists for chronic inflammatory joint disease
Daniel Wendling et al.
JOINT BONE SPINE (2008)
Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFα therapy
Valeria D'Ovidio et al.
JOURNAL OF CLINICAL VIROLOGY (2008)
Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab
Keisuke Ojiro et al.
JOURNAL OF GASTROENTEROLOGY (2008)
From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment
Ismail Sari et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease
E. J. Cepeda et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis
N. Viget et al.
GUT (2008)
Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient
Maria Esteve et al.
INFLAMMATORY BOWEL DISEASES (2007)
Infliximab and the risk of latent viruses reactivation in active Crohn's disease
Alessandro Lavagna et al.
INFLAMMATORY BOWEL DISEASES (2007)
Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection
Grigorios T. Sakellariou et al.
CLINICAL RHEUMATOLOGY (2007)
Infections during tumour necrosis factor-α blocker therapy for rheumatic diseases in daily practice:: a systematic retrospective study of 709 patients
C. Salliot et al.
RHEUMATOLOGY (2007)
Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus
H. Marotte et al.
RHEUMATOLOGY (2007)
Safe and effective application of anti-TNF-α in a patient infected with HIV and concomitant Crohn's disease
B. Beltran et al.
GUT (2006)
Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses
Gil Y. Melmed et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
GR Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis
J Torre-Cisneros et al.
RHEUMATOLOGY (2005)
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005
CH Smith et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Methods to avoid infections in patients with inflammatory bowel disease
FN Aberra et al.
INFLAMMATORY BOWEL DISEASES (2005)
Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study
NN Zein
JOURNAL OF HEPATOLOGY (2005)
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery
J Cosnes et al.
GUT (2005)
Epstein-Barr virus viral load in Crohn's disease - Effect of immunosuppressive therapy
D Reijasse et al.
INFLAMMATORY BOWEL DISEASES (2004)
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis
RS Wallis et al.
AIDS (2004)
Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-α therapy with infliximab for Crohn's disease
FS Velayos et al.
INFLAMMATORY BOWEL DISEASES (2004)
Disseminated primary varicella after initiation of infliximab for Crohn's disease
VS Leung et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Viral prophylaxis in organ transplant patients
M Slifkin et al.
DRUGS (2004)
A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease
JP Cezard et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2003)
Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate
JM van der Klooster et al.
INTENSIVE CARE MEDICINE (2003)
Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection
JR Peterson et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor α, and markers of immune activation in HIV-infected subjects receiving interleukin 2
BE Sha et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis
DM Aboulafia et al.
MAYO CLINIC PROCEEDINGS (2000)
Share Paper
